Mineralys Therapeutics Inc has seen a significant surge in market confidence, driven by a series of strategic financial maneuvers and positive analyst ratings, including a stock price target increase from Jefferies to $26.

Mineralys Therapeutics Inc. has seen a significant surge in its stock performance following promising trial data and a ‘Strong Buy’ recommendation from Wall Street analysts, positioning the company for potential growth in the healthcare sector.

Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company developing innovative treatments for uncontrolled hypertension through its pioneering work on aldosterone synthase inhibitors, with strong analyst support and potential for si…

Mineralys Therapeutics Inc. has reported better-than-expected earnings, beating analyst estimates with a GAAP EPS of -$0.66, despite flat revenue and ongoing challenges in the health care sector.

Mineralys Therapeutics, a clinical-stage biopharmaceutical company, is set to hold its Initial Public Offering (IPO) on February 9, 2023, with a focus on developing treatments for hypertension caused by excessive aldosterone levels.

Mineralys Therapeutics Inc. is navigating financial challenges while making bold strides towards innovation, including an NDA submission and $201 million equity raise, as it aims to bring its aldosterone synthase inhibitor to market.